Print ISSN:-2394-2789
Online ISSN:-2394-2797
CODEN : IJPCN9
Original Article
Author Details :
Volume : 7, Issue : 1, Year : 2020
Article Page : 26-31
https://doi.org/10.18231/j.ijpca.2020.004
Abstract
The aim of the research work was to develop a method for comparative evaluation of dissolution profile of two different brands of Teneligliptin hydrobromide hydrate drug in its formulations containing using UV Spectrophotometer. Simple, precise and accurate UV-spectrophotometric method was developed for Teneligliptin hydrobromide hydrate using optimized dissolution parameters like as 900mL of Phosphate buffer pH 6.8 as a dissolution medium and paddle (type II) apparatus at a stirring rate of 100 rpm. The drug release was evaluated by UV spectrophotometric method using 243.2nm as detection wavelength. Developed method obeyed Beer’s-Lambert’s law in the concentration range of 0.5-25 ?g/mL, with correlation coefficient value less than 1. The percent drug amount released estimated by proposed method was nearly 100%, found to be in good agreement with label claim of marketed tablet formulation. The proposed method were validated as per ICH guidelines with respect to accuracy, precision, LOD, LOQ and found to be within limits. The proposed method can be adopted for routine quality control test for estimation of drug in formulation. Also the statistical data analysis of percent drug release of brand 1 and 2 were compared with preexisting dissolution data of literature by using F-test and t-test.
Keywords: Teneligliptin hydrobromide, Spectrophotometric method.
How to cite : Chaudhar R K, Ganorkar A V, Dixit M P, Umekar M J, Comparative evaluation of dissolution profile of drug in its formulation by UV spectrophotometry. Int J Pharm Chem Anal 2020;7(1):26-31
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.